Saturday, July 11, 2026

Patent intelligence · US

US 9657267

Ex host maturation of germline stem cells

granted A61PA61P15/00A61P15/08
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 127
Patent details — US 9657267
Jurisdiction
US
Status
granted
Grant date
May 23, 2017
Expiration
May 18, 2037
Claims
7
CPC classes
A61P, A61P15/00, A61P15/08
View on Google Patents ↗

Quick answer

US 9657267 (Ex host maturation of germline stem cells) is held by PrimeGen Biotech LLC. Status: granted. Granted May 23, 2017. Expires May 18, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
7
CPC classes
A61P, A61P15/00, A61P15/08

More from PrimeGen Biotech LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12404275

    Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof

    PrimeGene (Beijing) Co., Ltd. · Expires Aug 28, 2045

    granted
  2. US 12383582

    Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases

    Prime Merger Sub, LLC · Expires Aug 7, 2045

    granted
  3. US 12377115

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Expires Jul 31, 2045

    granted
  4. US 12365719

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Expires Jul 17, 2045

    granted
  5. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Expires May 29, 2045

    granted
  6. US 12304898

    Quinolyl-containing compound and pharmaceutical composition, and use thereof

    PrimeGene (Beijing) Co., Ltd. · Expires May 15, 2045

    granted
  7. US 12234302

    Chitosan derivatives and methods for preparing the same

    PRIMEX EHF · Expires Feb 20, 2045

    granted
  8. US 12233119

    Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins

    Prime Bio, Inc. · Expires Feb 20, 2045

    granted

Frequently asked questions

What is US patent 9657267?

US 9657267 (Ex host maturation of germline stem cells) is held by PrimeGen Biotech LLC. Status: granted. Granted May 23, 2017. Expires May 18, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9657267?

PrimeGen Biotech LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 127 pharmaceutical patents for this assignee.

When does US 9657267 expire?

Our index shows an expiration date of May 18, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.